Ticker Details
Verastem, Inc. Verastem Inc is a biopharmaceutical company engaged in discovering and developing drugs to improve outcomes for patients with cancer. Its product candidates include duvelisib and defactinib.
IPO Date:	February 1, 2012
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$474.52M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.20 | 3.93%
Avg Daily Range (30 D):	$0.16 | 3.74%
Avg Daily Range (90 D):	$0.18 | 3.62%

Institutional Daily Volume
Avg Daily Volume:	.46M
Avg Daily Volume (30 D):	2.4M
Avg Daily Volume (90 D):	2.07M

Trade Size
Avg Trade Size (Sh.):	88
Avg Trade Size (Sh.) (30 D):	133
Avg Trade Size (Sh.) (90 D):	115

Institutional Trades
Total Institutional Trades:	963
Avg Institutional Trade:	$1.62M
Avg Institutional Trade (30 D):	$1.92M
Avg Institutional Trade (90 D):	$1.45M
Avg Institutional Trade Volume:	.15M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.77M
Avg Closing Trade (30 D):	$2M
Avg Closing Trade (90 D):	$1.49M
Avg Closing Volume:	166.95K

News

Nov 12, 2025 @ 6:00 PM KRAS Inhibitors Market to Witness Explosive Growth... Source: Delveinsight

Jul 23, 2025 @ 1:26 PM High‑Growth Oncology Market Projected For U... Source: Prnewswire

Mar 8, 2025 @ 12:33 PM Why the Global Cancer Market Could Surpass $900 Bi... Source: Prnewswire

Jul 24, 2024 @ 9:27 AM Why Enphase Energy Shares Are Trading Higher; Here... Source: Avi Kapoor

Jul 10, 2024 @ 6:51 PM Verastem, Inc. Investors: Company Investigated by ... Source: N/A

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-2.4	$-.37	$-.29
Diluted EPS	$-2.72	$-.46	$-.29
Revenue	$49.59M	$18.67M	$17.54M
Gross Profit
Net Income / Loss	$-193.96M	$-36.59M	$-32.92M
Operating Income / Loss	$-170.85M	$-44.9M	$-41.48M
Cost of Revenue
Net Cash Flow	$76.73M	$-39.44M	$67.28M
PE Ratio

Splits
Jun 01, 2023	1:12